Central Nervous System-related Conditions and Associated Healthcare Resource Use Among Japanese nmCRPC Patients Based on Retrospective Claims Data
**Background:** Japanese patients with prostate cancer are typically treated with primary androgen deprivation therapy (ADT), most commonly administered as a combination of a luteinizing hormone-releasing hormone (LHRH) agonist and an antiandrogen (AA). Since LHRH agonists and AA therapy can be main...
Saved in:
Main Authors: | Dianne A. Ledesma, Jonathan L. Chua, Susan S.H. Tang, Xiu W. Lim |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2023-10-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/001c.87550 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting AURKA with multifunctional nanoparticles in CRPC therapy
by: Bin Deng, et al.
Published: (2024-12-01) -
Immunology and the Central Nervous System
by: Carlos Barcia, et al.
Published: (2013-01-01) -
Oxidative Stress and the Central Nervous System
by: Marcello D’Ascenzo, et al.
Published: (2025-01-01) -
Cytokines and Myelination in the Central Nervous System
by: Thomas Schmitz, et al.
Published: (2008-01-01) -
PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
by: Kurnia Penta Seputra, et al.
Published: (2025-01-01)